Celltrion to Acquire US Biologics Plant to Counter Potential Pharma Tariffs
Celltrion has been selected as the preferred bidder to acquire a large biologics manufacturing plant in the United States —a strategic move aimed at insulating the company from potential US pharmaceutical tariffs.
US Pharmaceutical Tariffs | 30/07/2025 | By Dineshwori | 258
Celltrion Announces Three-Stage Strategy to Counter Trump's Pharma Tariff Plan
Celltrion has announced its response strategy to US President Donald Trump’s plan to impose tariffs on pharmaceuticals.
US Pharmaceutical Tariffs | 10/07/2025 | By Dineshwori | 305
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy